Biogen dumps doubtful Alzheimer’s drug after profit-killing FDA scandal
Enlarge / The outside of the headquarters of biotechnology firm Biogen in Cambridge, Massachusetts. Biotechnology firm Biogen is abandoning Aduhelm, its questionable Alzheimer’s drug that has floundered in the marketplace since its scandal-plagued regulatory approval in 2021 and brow-raising pricing. On Wednesday, the corporate introduced it had terminated its license for Aduhelm (aducanumab) and can […]


